Commissioning a four-dimensional Computed Tomography Simulator for minimum target size due to motion in the Anterior-Posterior direction: a procedure and treatment planning recommendations.

The purpose of this work is to develop a procedure for commissioning four-dimensional computed tomography (4DCT) algorithms for minimum target reconstruction size, to quantify the effect of anterior-posterior (AP) motion artifacts on known object reconstruction for periodic and irregular breathing patterns, and to provide treatment planning recommendations for target sizes below a minimum threshold. A mechanical platform enabled AP motion of a rod and lung phantom during 4DCT acquisition. Static, artifact-free scans of the phantoms were first acquired. AP sinusoidal and patient breathing motion was applied to obtain 4DCT images. 4DCT reconstruction artifacts were assessed by measuring the apparent width and angle of the rod. Comparison of known tumor diameters and volumes between the static image parameters with the 4DCT image sets was used to quantify the extent of AP reconstruction artifact and contour deformation. Examination of the rod width, under sinusoidal motion, found it was best represented during the inhale and exhale phases for all periods and ranges of motion. From the gradient phases, the apparent width of the rod decreased with increasing amplitude and decreasing period. The rod angle appeared larger on the reconstructed images due to the presence of motion artifact. The apparent diameters of the spherical tumors on the gradient phases were larger/equivalent than the true values in the AP/LR direction, respectively, while the exhale phase consistently displayed the spheres at the approximately correct diameter. The Eclipse calculated diameter matched closely with the true diameter on the exhale phase and was found to be larger on the inhale, MIP, and Avg scans. The procedure detailed here may be used during the acceptance and commissioning period of a computed tomography simulator or retroactively when implementing a SBRT program to determine the minimum target size that can be reliably reconstructed.

Evaluation of kidney motion and target localization in abdominal SBRT patients.

The purpose of this study was to evaluate bilateral kidney and target translational/rotational intrafraction motion during stereotactic body radiation therapy treatment delivery of primary renal cell carcinoma and oligometastatic adrenal lesions for patients immobilized in the Elekta BodyFIX system. Bilateral kidney motion was assessed at midplane for 30 patients immobilized in a full-body dual-vacuum-cushion system with two patients immobilized via abdominal compression. Intrafraction motion was assessed for 15 patients using kilovoltage cone-beam computed tomography (kV-CBCT) datasets (n = 151) correlated to the planning CT. Patient positioning was corrected for translational and rotational misalign-ments using a robotic couch in six degrees of freedom if setup errors exceeded 1mm and 1°. Absolute bilateral kidney motion between inhale and exhale 4D CT imaging phases for left-right (LR), superior-inferior (SI), and anterior-posterior (AP) directions was 1.51 ± 1.00 mm, 8.10 ± 4.33 mm, and 3.08 ± 2.11 mm, respec-tively. Residual setup error determined across CBCT type (pretreatment, intrafrac-tion, and post-treatment) for x (LR), y (SI), and z (AP) translations was 0.63 ± 0.74 mm, 1.08± 1.38 mm, and 0.70 ± 1.00 mm; while for x (pitch), y (roll), and z (yaw) rotations was 0.24 ± 0.39°, 0.19 ± 0.34°, and 0.26 ± 0.43°, respectively. Targets were localized to within 2.1 mm and 0.8° 95% of the time. The frequency of misalignments in the y direction was significant (p < 0.05) when compared to the x and z directions with no significant difference in translations between IMRT and VMAT. This technique is robust using BodyFIX for patient immobilization and reproducible localization of kidney and adrenal targets and daily CBCT image guidance for correction of positional errors to maintain treatment accuracy.

Evaluation of lens dose from anterior electron beams: comparison of Pinnacle and Gafchromic EBT3 film.

Lens dose is a concern during the treatment of facial lesions with anterior electron beams. Lead shielding is routinely employed to reduce lens dose and minimize late complications. The purpose of this work is twofold: 1) to measure dose pro-files under large-area lead shielding at the lens depth for clinical electron energies via film dosimetry; and 2) to assess the accuracy of the Pinnacle treatment planning system in calculating doses under lead shields. First, to simulate the clinical geometry, EBT3 film and 4 cm wide lead shields were incorporated into a Solid Water phantom. With the lead shield inside the phantom, the film was positioned at a depth of 0.7 cm below the lead, while a variable thickness of solid water, simulating bolus, was placed on top. This geometry was reproduced in Pinnacle to calculate dose profiles using the pencil beam electron algorithm. The measured and calculated dose profiles were normalized to the central-axis dose maximum in a homogeneous phantom with no lead shielding. The resulting measured profiles, functions of bolus thickness and incident electron energy, can be used to estimate the lens dose under various clinical scenarios. These profiles showed a minimum lead margin of 0.5 cm beyond the lens boundary is required to shield the lens to ≤ 10% of the dose maximum. Comparisons with Pinnacle showed a consistent overestimation of dose under the lead shield with discrepancies of ~ 25% occur-ring near the shield edge. This discrepancy was found to increase with electron energy and bolus thickness and decrease with distance from the lead edge. Thus, the Pinnacle electron algorithm is not recommended for estimating lens dose in this situation. The film measurements, however, allow for a reasonable estimate of lens dose from electron beams and for clinicians to assess the lead margin required to reduce the lens dose to an acceptable level.

Automated air kerma strength quality assurance of permanent seed implant prostate brachytherapy sources using vendor autoradiographs.

PURPOSE: To develop a novel quality assurance (QA) program to determine the air kerma strength (AKS) of brachytherapy seeds within preloaded needles using autoradiographs alone, without jeopardizing sterility or necessitating procedural changes either by the vendor or in the operating room. METHODS AND MATERIALS: Digital autoradiographs of QA seed orders and sterile preloaded needles were acquired. Regions of interest of each preloaded seed were determined through an iterative scanning process identifying changes from background levels to radioactivity exposure. Average exposure values through the center of each region of interest were fitted with a Gaussian curve and Full Width at Half Maximums (FWHMs) were calculated. The two-dimensional exposure-scaled FWHM (Exp2D) measurements for the QA seed orders were plotted against measured AKS values and related using a linear curve fit that was adjusted using the third-party assay average AKS and applied as a calibration curve to convert Exp2D to AKS. RESULTS: Estimated seed AKS was found to have a strong dependence on position within the holding tray because of imager positioning inconsistencies. Calculated seed AKS for patient-specific seed orders using the curve scaling factor varied from the nominal order AKS by 1.1 ± 0.9% and from the third-party assay measurements by 0.0 ± 0.4%. CONCLUSIONS: This work depicts a clinically useful tool to aid in QA of preloaded brachytherapy permanent seed implant needles without compromising sterility or increasing clinical workloads. With this procedure, each individual seed's AKS can be verified automatically before a patient's scheduled implant or retroactively when auditing patient records.

Dosimetric Impact of Using a Virtual Couch Shift for Online Correction of Setup Errors for Brain Patients on an Integrated High-Field Magnetic Resonance Imaging Linear Accelerator.

PURPOSE: To quantify the dosimetric impact of using virtual couch shift (VCS) for correcting setup errors in glioblastoma multiforme (GBM) patients treated on a magnetic resonance imaging (MRI)-linac. METHODS AND MATERIALS: Six GBM patients treated with 60 Gy (30 fractions) were selected for this simulation study. For each case, 2 reference plans were generated in the MRL treatment planning system: With (WIB) and with no (NOB) MRI B field present. Subsequently, 2-mm, 4-mm, and 6-mm translational errors were simulated and corrected for using a VCS method based on shift-only, warm start segment weight (SWO), and segment weight and shape (SSO) optimization. The resulting distributions were compared with the reference plan using planning target volume (PTV) homogeneity index (HI), conformity index (CI), organs at risk (OAR) maximum dose (D0.01cc), and OAR median dose (D50). A simulated 30-fraction treatment was constructed to evaluate the cumulative effect of daily corrections. Feasibility and workflow for correcting rotations were also assessed. RESULTS: All reference plans were deemed clinically acceptable with respect to PTV and OAR objectives. The difference in HI (ΔHI) between corrected and reference was not statistically significant between WIB and NOB (P=.89). The average ΔHI was +0.8%, -0.1%, and -1.0% for shift-only, SWO, and SSO, respectively, with a statistically significant difference (P<.001) for shift-only versus SWO and SSO. The CI remained unchanged (mean ΔCI = -0.01) between the corrected and reference plans, with no statistically significant dependence on magnetic field presence, correction method, or shift magnitude or orientation. The brainstem D50 on average decreased with SWO and SSO; however, D0.01cc increased by a median value of 1.2%, 1.9%, and 2.0% for shift-only, SWO, and SSO, respectively. For other OARs, D0.01cc decreased using SWO or SSO. For the simulated treatment and rotational corrections, similar trends were measured. CONCLUSION: For translational errors in brain MRI-linac radiation therapy, the VCS method is an acceptable correction strategy, but caution must be used in particular for serial organs where maximum doses are most relevant. The effect of the magnetic field on relative changes between corrected versus reference plans is not clinically relevant.

Implementation of a volumetric modulated arc therapy treatment planning solution for kidney and adrenal stereotactic body radiation therapy.

To develop a volumetric modulated arc therapy (VMAT) treatment planning solution in the treatment of primary renal cell carcinoma and oligometastatic adrenal lesions with stereotactic body radiation therapy. Single-arc VMAT plans (n = 5) were compared with clinically delivered step-and-shoot intensity-modulated radiotherapy (IMRT) with planning target volume coverage normalized between techniques. Target volume conformity, organ-at-risk (OAR) dose, treatment time, and monitor units were compared. A VMAT planning solution, created from a combination of arc settings and optimization constraints, auto-generated treatment plans in a single optimization. The treatment planning solution was evaluated on 15 consecutive patients receiving kidney and adrenal stereotactic body radiation therapy. Treatment time was reduced from 13.0 ± 2.6 to 4.0 ± 0.9 minutes for IMRT and VMAT, respectively. The VMAT planning solution generated treatment plans with increased target homogeneity, improved 95% conformity index, and a reduced maximum point dose to nearby OARs but with increased intermediate dose to distant OARs. The conformity of the 95% isodose improved from 1.32 ± 0.39 to 1.12 ± 0.05 for IMRT and VMAT treatment plans, respectively. Evaluation of the planning solution showed clinically acceptable dose distributions for 13 of 15 cases with tight conformity of the prescription isodose to the planning target volume of 1.07 ± 0.04, delivering minimal dose to OARs. The introduction of a stereotactic body radiation therapy VMAT treatment planning solution improves the efficiency of planning and delivery time, producing treatment plans of comparable or superior quality to IMRT in the case of primary renal cell carcinoma and oligometastatic adrenal lesions.

Intensity-modulated stereotactic radiosurgery for arteriovenous malformations: guidance for treatment planning.

BACKGROUND: Stereotactic Radiosurgery (SRS) is a common tool used to treat Arteriovenous Malformations (AVMs) in anatomical locations associated with a risk of surgical complications. Despite high rates of clinical effectiveness, SRS carries a risk of toxicity as a result of radiation injury to brain tissue. The use of intensity-modulated radiotherapy (IMRT) has increased because it may lead to improved PTV conformity and better Normal Tissue (NT) sparing compared to 3D Conformal Radiotherapy (3DCRT). The aim of this study was twofold: 1) to develop simple patient stratification rules for the recommendation of IMRT planning strategies over 3DCRT in the treatment of AVMs with SRS; and 2) to estimate the impact of IMRT in terms of toxicity reduction using retrospectively reported data for symptomatic radiation injury following SRS. METHODS: Thirty-one AVM patients previously treated with 3DCRT were replanned in a commercial treatment planning system using 3DCRT and static gantry IMRT with identical beam arrangements. The radiotherapy planning metrics analyzed included AVM volume, diameter, and volume to surface area ratio. The dosimetric endpoints analyzed included conformity index improvements and NT sparing measured by the maximum NT dose, and the volume of surrounding tissue that received 7Gy and 12Gy. RESULTS: Our analysis revealed stratified subsets of patients for IMRT that were associated with improved conformity, and those that were associated with decreased doses to normal tissue. The stratified patients experienced an improvement in conformity index by -6-68%, a reduction in the maximum NT dose by -0.5-12.3%, a reduction in the volume of NT receiving 7Gy by 1-8 cc, and a reduction in the volume of NT receiving 12Gy by 0-3.7 cc. The reduction in NT receiving 12Gy translated to a theoretical decrease in the probability of symptomatic injury by 0-9.3%. CONCLUSIONS: This work indicates the potential for significant patient improvements when treating AVMs and provides rules to predict which patients are likely to benefit from IMRT.